Drug intelligence / Profile preview

TNX-3600

Development stage: Preclinical
Lead developer: Tonix Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous (expected; Typical For Monoclonal Antibodies)

Overview

TNX-3600 is a fully human monoclonal antibody developed by Tonix Pharmaceuticals in collaboration with Columbia University. It is designed as an antiviral agent for the treatment and prevention of COVID-19. The antibody was generated from SARS-CoV-2 positive asymptomatic individuals or COVID-19 convalescent patients using a proprietary human hybridoma fusion platform. Its mechanism of action involves immunostimulation and T lymphocyte stimulation, with specific activity as an inhibitor of the SARS-CoV-2 spike (S) protein, thereby neutralizing the virus and potentially preventing infection or disease progression. As of now, it remains in preclinical development for COVID-19[1][2][3][6].

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on TNX-3600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNX-3600.

Explore the full profile